PsA-2 trial
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor
Actionable Insights Powered by AI
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor